{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T05:18:10Z","timestamp":1784524690156,"version":"3.55.0"},"reference-count":37,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Pfizer Inc"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2021,5,22]]},"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Pain is a core domain of psoriatic arthritis (PsA). This post hoc analysis evaluated time to pain improvement and the impact of baseline pain severity on pain response in patients with PsA receiving tofacitinib.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data from two trials (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01877668\">NCT01877668<\/jats:ext-link>;  <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01882439\">NCT01882439<\/jats:ext-link>) in patients receiving tofacitinib 5\u2009mg twice daily, placebo switching to tofacitinib 5\u2009mg twice daily at month 3 (placebo-to-tofacitinib) or adalimumab (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01877668\">NCT01877668<\/jats:ext-link> only) were included. Improvement in pain (\u226530%\/\u226550% decrease from baseline in Visual Analogue Scale pain score) was assessed; median time to initial (first post-baseline visit)\/continued (first two consecutive post-baseline visits) pain improvement was estimated (Kaplan-Meier) for all treatment arms. A parametric model was used to determine the relationship between baseline pain severity and time to pain response in patients receiving tofacitinib.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At month 3, more patients experienced pain improvements with tofacitinib\/adalimumab versus placebo. Median days (95%\u2009CI) to initial\/continued pain improvements of \u226530%\u2009and \u226550%, respectively, were 55 (29\u201357)\/60 (57\u201385) and 85 (57\u201392)\/171 (90\u2013not estimable (NE)) for tofacitinib, versus 106 (64\u2013115)\/126 (113\u2013173) and 169 (120\u2013189)\/NE (247\u2013NE) for placebo-to-tofacitinib. Pain improvements were also experienced more quickly for adalimumab versus placebo. Predicted time to \u226530%\/\u226550%\u2009pain improvement was shorter in patients with higher baseline pain versus lower baseline pain (tofacitinib arm only).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In patients with PsA, pain improvements were experienced by more patients, and more rapidly, with tofacitinib and adalimumab versus placebo. In those receiving tofacitinib, higher baseline pain was associated with faster pain improvements.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2021-001609","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T12:03:02Z","timestamp":1625486582000},"page":"e001609","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib"],"prefix":"10.1136","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct01877668","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01882439","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01877668","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01877668","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01882439","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01976364","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Kurt","family":"de Vlam","sequence":"first","affiliation":[{"name":"Department of Rheumatology, UZ Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G","family":"Bushmakin","sequence":"additional","affiliation":[{"name":"Global Research and Development, Pfizer Inc, Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph C","family":"Cappelleri","sequence":"additional","affiliation":[{"name":"Global Research and Development, Pfizer Inc, Groton, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6630-1477","authenticated-orcid":false,"given":"Roy","family":"Fleischmann","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C","family":"Taylor","sequence":"additional","affiliation":[{"name":"Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, Oxfordshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valderilio","family":"Azevedo","sequence":"additional","affiliation":[{"name":"Departamento de Cl\u00ednica M\u00e9dica, Universidade Federal do Paran\u00e1, Curitiba, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Fallon","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Rheumatology, Pfizer Inc, Kirkland, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Woolcott","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Gastroenterology, Inflammation and Immunology, Pfizer Inc, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J","family":"Mease","sequence":"additional","affiliation":[{"name":"Swedish Medical Center\/Providence St. Joseph Health and University of Washington, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"key":"2025090313594819000_7.2.e001609.1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","article-title":"The epidemiology of psoriatic arthritis","volume":"41","author":"Ogdie","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"2025090313594819000_7.2.e001609.2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025090313594819000_7.2.e001609.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.07.023"},{"key":"2025090313594819000_7.2.e001609.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557"},{"key":"2025090313594819000_7.2.e001609.5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/1744666X.2018.1468252","article-title":"Quality of life in psoriatic arthritis","volume":"14","author":"Gudu","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"2025090313594819000_7.2.e001609.6","first-page":"1842","article-title":"Comparison of disability and quality of life in rheumatoid and psoriatic arthritis","volume":"28","author":"Sokoll","year":"2001","journal-title":"J Rheumatol"},{"key":"2025090313594819000_7.2.e001609.7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.semarthrit.2017.05.010","article-title":"The psychosocial burden of psoriatic arthritis","volume":"47","author":"Husni","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2025090313594819000_7.2.e001609.8","doi-asserted-by":"publisher","DOI":"10.1080\/03009740500343260"},{"key":"2025090313594819000_7.2.e001609.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210242"},{"key":"2025090313594819000_7.2.e001609.10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180014","article-title":"Pain and pain mechanisms in patients with inflammatory arthritis: a Danish nationwide cross-sectional DANBIO registry survey","volume":"12","author":"Rifbjerg-Madsen","year":"2017","journal-title":"PLoS One"},{"key":"2025090313594819000_7.2.e001609.11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0123582"},{"key":"2025090313594819000_7.2.e001609.12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s40271-017-0221-4","article-title":"Important treatment outcomes for patients with psoriatic arthritis: a multisite qualitative study","volume":"10","author":"Dures","year":"2017","journal-title":"Patient"},{"key":"2025090313594819000_7.2.e001609.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-209057"},{"key":"2025090313594819000_7.2.e001609.14","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/acr.23693","article-title":"Pain mechanisms and ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: a prospective cohort study","volume":"71","author":"H\u00f8jgaard","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313594819000_7.2.e001609.15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010650"},{"key":"2025090313594819000_7.2.e001609.16","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102053"},{"key":"2025090313594819000_7.2.e001609.17","first-page":"S64","article-title":"Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander\/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI)","volume":"63 Suppl 11","author":"Mease","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313594819000_7.2.e001609.18","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X132488"},{"key":"2025090313594819000_7.2.e001609.19","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1007\/s10067-019-04656-5","article-title":"Neuropathic-like pain in psoriatic arthritis: evidence of abnormal pain processing","volume":"38","author":"Ramjeeawon","year":"2019","journal-title":"Clin Rheumatol"},{"key":"2025090313594819000_7.2.e001609.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.08.012"},{"key":"2025090313594819000_7.2.e001609.21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1515\/sjpain-2019-0054","article-title":"Revised chronic widespread pain criteria: development from and integration with fibromyalgia criteria","volume":"20","author":"Wolfe","year":"2019","journal-title":"Scand J Pain"},{"key":"2025090313594819000_7.2.e001609.22","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000808","article-title":"Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond","volume":"5","author":"Strand","year":"2019","journal-title":"RMD Open"},{"key":"2025090313594819000_7.2.e001609.23","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000806","article-title":"Tofacitinib or adalimumab versus placebo: patient-reported outcomes from opal OPAL Broaden - a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs","volume":"5","author":"Strand","year":"2019","journal-title":"RMD Open"},{"key":"2025090313594819000_7.2.e001609.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2007.09.005"},{"key":"2025090313594819000_7.2.e001609.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975"},{"key":"2025090313594819000_7.2.e001609.26","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"key":"2025090313594819000_7.2.e001609.27","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40744-020-00209-4","article-title":"Safety and efficacy of tofacitinib in patients with active psoriatic arthritis: interim analysis of OPAL Balance, an open-label, long-term extension study","volume":"7","author":"Nash","year":"2020","journal-title":"Rheumatol Ther"},{"key":"2025090313594819000_7.2.e001609.28","unstructured":"Rosner B . Fundamentals of biostatistics. 7th ed. Boston, MA: Brooks Kole, Cengage Learning, 2018."},{"key":"2025090313594819000_7.2.e001609.29","doi-asserted-by":"publisher","DOI":"10.2307\/2281868"},{"key":"2025090313594819000_7.2.e001609.30","first-page":"163","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother Rep"},{"key":"2025090313594819000_7.2.e001609.31","doi-asserted-by":"publisher","DOI":"10.2307\/2344317"},{"key":"2025090313594819000_7.2.e001609.32","doi-asserted-by":"crossref","unstructured":"Hosmer DW , Lemeshow S , May S . Applied survival analysis: regression modeling of time-to-event data. 2nd ed. Hoboken, NJ: John Wiley & Sons, Inc, 2008.","DOI":"10.1002\/9780470258019"},{"key":"2025090313594819000_7.2.e001609.33","first-page":"S240","article-title":"Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP)","volume":"63 Suppl 11","author":"Hawker","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313594819000_7.2.e001609.34","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001042"},{"key":"2025090313594819000_7.2.e001609.35","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3390\/jcm8060831","article-title":"Achieving pain control in rheumatoid arthritis with baricitinib or adalimumab plus methotrexate: results from the RA-BEAM trial","volume":"8","author":"Taylor","year":"2019","journal-title":"J Clin Med"},{"key":"2025090313594819000_7.2.e001609.36","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-eular.994","article-title":"Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo","volume":"79","author":"Gladman","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025090313594819000_7.2.e001609.37","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jclinepi.2013.10.025","article-title":"Dependence of the minimal clinically important improvement on the baseline value is a consequence of floor and ceiling effects and not different expectations by patients","volume":"67","author":"Ward","year":"2014","journal-title":"J Clin Epidemiol"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2021-001609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:59:56Z","timestamp":1756933196000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2021-001609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,7,5]]},"published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1136\/rmdopen-2021-001609"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2021-001609","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}